We will unlock the mysteries of life in a research environment where the most updated equipment is utilized such as the next generation sequencer, a mass spectrometer combined with radioisotope (RI) capability.

Automatic Robotics

Sample spot for enzyme reactions and Matrix Assisted Laser Desorption/Ionization(MALDI/TOFMS ) done by automation Robotics. This automation makes high throughput screening psooible at our owncampus. For Enzyme-linked Immunosorbent assays (ELISA), robotic processors can dispense twelve samples at a time with minimum cross-contamination and high reproducibility.

Confocal Microscope

We localize protein in the cell using fluorescent-labeled antibodies and protein. We also use time-lapse imaging in the live cell. With the fluorescent microscopy system, we can detect multiple biomarkers with different fluorescent tags.

High-speed Sequencer

We have three Illumina Genome Analyzers which can accurately sequence over 50Gbp of genome in one week. We are using these sequences for epigenome analysis, genome analysis, and transcription regulation.

Mass Spectrometer

We are using MALDI-TOFMS, LC/MS/MS(Orbitrap(Ion trap)), LC/MS/MS (Triple quadrupole), and High Throughput Peptide Immunoaffinity, High-Sensitivity complex Protein Analysis, and highly sensitive mass spectrometry. This equipment is also used for the analysis of post-translational modifications of proteins and the.analysis of endogenous protein complex using highly specific monoclonal antibody.


RI Facility PET

In RI facility, thirteen different radioisoptopes are permitted to use for our research. We can perform a variety of analysis including EMSA, gel shift assay, cytolysis inhibition assay using antibodies, binding assay, or PET. Our goal is to develop diagnostic drugs for cancer combining monoclonal antibodies and animal PET imaging. By administrating RI labeled antibodies to an animal with cancer, we can precisely locate the tumor using PET imaging. By manipulating the monoclonal antibodies, this method can also be used for cancer treatment as radio immunotherapy (RIT). This will be a quite useful tool to develop antibodies for cancer treatment.

FACS

It is used for analyzing cell cycles and antibody screening for membrane antigens. We can target specific membrane proteins which appear in cancer during antibody screening. We are developing high-affinity antibodies which can recognize proteins in cell membranes in the human body.